On the stock market since 2020, it operates in the world of health and science. It has 91 employees. Now — the numbers.
This is an established company with proven profits.
The gap is $99.7M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 71% — still a thick cushion, though costs have been eating into it lately.
Over the last 12 months, company executives reported 6 buys and 3 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 3,309.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, GNRSW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GNRSW is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.